| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1606 | |
| Phytochemical name or plant extracts | Scutellaria barbata extract (BZL101) | |
| PMID | 20054647 | |
| Literature evidence | In conclusion, oral administration of BZL101 was safe, well tolerated, and showed promising clinical evidence of anticancer activity in this heavily pretreated population of women with MBC. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Aqueous extract | |
| Source of phytochemicals or plant Extracts | Scutellaria barbata | |
| Geographical availability | Assam, Bangladesh, China South-Central, China Southeast, East Himalaya, Japan, Korea, Laos, Myanmar, Nepal, Taiwan, Thailand, Vietnam, West Himalaya | |
| Plant parts | Herb | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | In summary, this second phase 1 clinical trial demonstrated that BZL101 is safe and well tolerated with encouraging evidence of clinical activity. With an improved formulation of BZL101, a phase 2 clinical trial for women with MBC is planned. | |
| Cell line/ mice model | Clinical trial | |
| Additional information | The MTD was not reached, thus per protocol, the MTD was defined as the maximum administered dose of BZL101 40 g/day. | |
| PubChem ID | NA | |
| Additional PMIDs | 19962306 20574166 27240278 30449170 21360416 20078074 29925100 16012772 17111207 16273300 18305410 20054647 21509784 25026725 26875645 30384539 32922506 32351594 32416245 24734104 20558270 24498964 30444060 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:458159-1 | |
| Safety | NA |